Streetbeat News

WUXAY

Wuxi AppTec Co. Ltd.

http://www.wuxiapptec.com.cn/

CEO

Ge Li

Industry

Testing Laboratories

Open

6.08

Mkt cap

19B

Volume

128

High

6.10

P/E Ratio

16.05

52-wk high

8.89

Low

6.08

Div yield

0.02

52-wk low

4.05

WuXi AppTec's Couvet site in Switzerland has been awarded a silver medal in the 2024 EcoVadis business sustainability ratings, showcasing the company's commitment to ESG priorities.

Portfolio Pulse from

November 14, 2024 | 1:15 pm

WuXi Advanced Therapies (WuXi ATU), a subsidiary of WuXi AppTec, received FDA approval to manufacture AMTAGVI for Iovance Biotherapeutics (NASDAQ:IOVA), marking a significant milestone in the treatment of advanced melanoma. AMTAGVI, a one-time, individualized T cell therapy, is the first of its kind approved by the FDA for a solid tumor cancer. This approval positions WuXi ATU's Philadelphia site as the first U.S. external manufacturing and third-party contract testing organization for such therapy. Iovance, committed to developing TIL cell therapies, celebrates this as a step towards addressing unmet needs in advanced melanoma treatment.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:35 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.